AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23857683 — intervention group
Group type: COMPARATOR
Intervention: Löwenstein-Jensen medium
Number of subjects: 0
Study 22167112 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of nicotine replacement therapy (NRT; nicotine patch) + 6 sessions of motivational interviewing (MI)
Number of subjects: 430
Study 22167112 — intervention group
Group type: COMPARATOR
Intervention: NRT + standard care
Number of subjects: 430
Study 22167112 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT (nicotine patch)
Number of subjects: 430
Study 18505180 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT+ddC
Number of subjects: 3195
Study 18505180 — intervention group
Group type: COMPARATOR
Intervention: AZT monotherapy
Number of subjects: 3195
Study 18505180 — intervention group
Group type: COMPARATOR
Intervention: AZT+ddl
Number of subjects: 3195
Study 17175484 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 0
Study 14578869 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant HCV E1 (20 mug) administered intramuscularly at weeks 0, 4, 8, 12, and 24.
Number of subjects: 35
Study 14578869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (alum only) administered intramuscularly at weeks 0, 4, 8, 12, and 24.
Number of subjects: 35
Study 10714552 — intervention group
Group type: COMPARATOR
Intervention: G-CSF from day 0 to day 13 after HDCT (arm A)
Number of subjects: 34
Study 10714552 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF from day 0 to day 6 and GM-CSF from day 7 to day 13 (arm B)
Number of subjects: 34
Study 9760788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from ILD patients
Number of subjects: 43
Study 9760788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from AFL patients
Number of subjects: 43
Study 9760788 — intervention group
Group type: EXPERIMENTAL
Intervention: Sera from DIPF patients
Number of subjects: 43
Study 9760788 — intervention group
Group type: COMPARATOR
Intervention: Control sera from healthy individuals
Number of subjects: 43
Study 1376841 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (n = 26)
Number of subjects: 52
Study 1376841 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (n = 26)
Number of subjects: 52
Study 3899368 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg Nimodipine
Number of subjects: 43
Study 3899368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31619305 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (specific antipsychotics not detailed) over an 18-month period
Number of subjects: 765
Study 31619305 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variations related to obesity-risk genes
Number of subjects: 765
Study 31619305 — intervention group
Group type: EXPERIMENTAL
Intervention: GWAS analysis
Number of subjects: 765
Study 29278718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy for Obesity (CRT-O)
Number of subjects: 80
Study 29278718 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 80
Study 25800045 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Citrullus colocynthis extract oil
Number of subjects: 60
Study 25800045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23861132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilirubin levels in patients with CAD (n=145)
Number of subjects: 221
Study 23861132 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=76)
Number of subjects: 221
Study 23861132 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bilirubin levels
Number of subjects: 221
Study 23861132 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bilirubin levels
Number of subjects: 221
Study 22781295 — intervention group
Group type: EXPERIMENTAL
Intervention: LACJ therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + Jinghuaweikang 3 capsules)
Number of subjects: 565
Study 22781295 — intervention group
Group type: COMPARATOR
Intervention: LACB therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg)
Number of subjects: 565
Study 22781295 — intervention group
Group type: COMPARATOR
Intervention: LAC therapy (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg)
Number of subjects: 565
Study 22781295 — intervention group
Group type: EXPERIMENTAL
Intervention: LACJ therapy
Number of subjects: 565
Study 22781295 — intervention group
Group type: COMPARATOR
Intervention: LACB therapy
Number of subjects: 565
Study 22781295 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of antibiotic-resistant genes
Number of subjects: 565
Study 20219104 — intervention group
Group type: EXPERIMENTAL
Intervention: Top Grub card game and healthy eating curriculum
Number of subjects: 1133
Study 20219104 — intervention group
Group type: COMPARATOR
Intervention: Control schools (no intervention)
Number of subjects: 1133
Study 18657673 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 118
Study 18657673 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 118
Study 18657673 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sinus rhythm at follow-up
Number of subjects: 118
Study 18657673 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation at follow-up
Number of subjects: 118
Study 15876828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure bicarbonate dialysis (BD)
Number of subjects: 64
Study 15876828 — intervention group
Group type: COMPARATOR
Intervention: On‐line predilution hemofiltration (HF)
Number of subjects: 64
Study 12577049 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 207
Study 12577049 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 207
Study 10234558 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologists
Number of subjects: 68
Study 10234558 — intervention group
Group type: COMPARATOR
Intervention: Control group (other physicians)
Number of subjects: 68
Study 8894500 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg NN623
Number of subjects: 0
Study 8894500 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg A4166
Number of subjects: 0
Study 8894500 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg NN623
Number of subjects: 0
Study 1927487 — intervention group
Group type: EXPERIMENTAL
Intervention: Yunfujing
Number of subjects: 131
Study 1927487 — intervention group
Group type: COMPARATOR
Intervention: Armillaria mellea vabi (control)
Number of subjects: 131
Study 6804161 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives with 50 micrograms or less of ethinyl estradiol
Number of subjects: 2430
Study 6804161 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation containing 20 micrograms ethinyl estradiol
Number of subjects: 2430
Study 6804161 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation containing 400 micrograms norethisterone acetate
Number of subjects: 2430
Study 6804161 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone preparations
Number of subjects: 2430
Study 6804161 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing preparations
Number of subjects: 2430
Study 31919724 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIDE intervention (literacy-sensitive, provider-focused health communication)
Number of subjects: 410
Study 31919724 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes education (control)
Number of subjects: 410
Study 31919724 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIDE intervention
Number of subjects: 410
Study 31603428 — intervention group
Group type: EXPERIMENTAL
Intervention: I-CBT
Number of subjects: 100
Study 31603428 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care (I-CBT followed by face-to-face CBT if needed)
Number of subjects: 100
Study 31603428 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' group with largest median reduction of fatigue
Number of subjects: 100
Study 27660368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NHE)
Number of subjects: 30
Study 27660368 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip extension (HE) training
Number of subjects: 30
Study 27660368 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 25559915 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training three times weekly
Number of subjects: 131
Study 25559915 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 131
Study 24165896 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric gargle
Number of subjects: 80
Study 24165896 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine gargle
Number of subjects: 80
Study 22475046 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 1155
Study 22475046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1155
Study 19893122 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education on CHF topics (general information, symptoms, dietary nutrition, medicative therapy)
Number of subjects: 57
Study 19893122 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Number of subjects: 57
Study 19893122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic education)
Number of subjects: 57
Study 18179756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide
Number of subjects: 178
Study 15133425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 5804
Study 11795438 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) for 3 months
Number of subjects: 0
Study 9501267 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylalanine‐complemented amino acid supplement (increased blood phenylalanine concentrations to 1000-1300 mumol/L for 3 months)
Number of subjects: 16
Study 9501267 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 16
Study 7655966 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide as a contrast medium for intra-arterial digital subtraction lower limb angiography
Number of subjects: 11
Study 2679938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (health education promoting a cholesterol-lowering diet, smoking cessation, weight control, physical activity, treatment of arterial hypertension)
Number of subjects: 19409
Study 2679938 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19409
Study 1098358 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2000 international units daily for 3 months)
Number of subjects: 226
Study 1098358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 29699792 — intervention group
Group type: EXPERIMENTAL
Intervention: GARDASIL (quadrivalent human papillomavirus vaccine)
Number of subjects: 100
Study 29699792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 100
Study 26229044 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 14
Study 26229044 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping (PT)
Number of subjects: 14
Study 24286482 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 100
Study 24286482 — intervention group
Group type: COMPARATOR
Intervention: Transobturator tape (TOT)
Number of subjects: 100
Study 24286482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed urinary incontinence subgroup
Number of subjects: 100
Study 24286482 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence subgroup
Number of subjects: 100
Study 22274550 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk test meal
Number of subjects: 17
Study 22274550 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein test meal
Number of subjects: 17
Study 22274550 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey test meal
Number of subjects: 17
Study 20337618 — intervention group
Group type: EXPERIMENTAL
Intervention: ramosetron 0.3 mg (n = 42)
Number of subjects: 84
Study 20337618 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg (n = 42)
Number of subjects: 84
Study 18354860 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable hemodynamic monitoring (IHM)
Number of subjects: 0
Study 18354860 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15842968 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare metal stents
Number of subjects: 0
Study 15842968 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting stents
Number of subjects: 0
Study 11712327 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 23
Study 9424913 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 270
Study 7899034 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion detection system
Number of subjects: 0
Study 7899034 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement aftereffect (MAE)
Number of subjects: 0
Study 3596789 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 5819
Study 3596789 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of the beta-blocker oxprenolol
Number of subjects: 5819
Study 3596789 — intervention group
Group type: EXPERIMENTAL
Intervention: Better blood pressure control
Number of subjects: 5819
Study 3596789 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ST segment depression and complete left bundle branch block in entry ECG
Number of subjects: 5819
Study 3596789 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal blood pressure control
Number of subjects: 5819
Study 2539345 — intervention group
Group type: COMPARATOR
Intervention: CCNU alone
Number of subjects: 44
Study 2539345 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU with BENZO
Number of subjects: 44
Study 30406291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day psychoeducation group
Number of subjects: 204
Study 30406291 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week psychoeducation group
Number of subjects: 204
Study 30406291 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 29019894 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-course concurrent chemoradiotherapy (CCRT)
Number of subjects: 155
Study 29019894 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (SCRT)
Number of subjects: 155
Study 29019894 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-course concurrent chemoradiotherapy (CCRT) in pT3-4 pN1-3 cM0 subgroup
Number of subjects: 155
Study 29019894 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy (SCRT) in pT3-4 pN1-3 cM0 subgroup
Number of subjects: 155
Study 26320194 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 100
Study 26320194 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 100
Study 26320194 — intervention group
Group type: COMPARATOR
Intervention: aripiprazole and risperidone
Number of subjects: 100
Study 23509175 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cleansing with 4.0% chlorhexidine
Number of subjects: 29760
Study 23509175 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-cleansing with 4.0% chlorhexidine
Number of subjects: 29760
Study 23509175 — intervention group
Group type: COMPARATOR
Intervention: Dry and clean cord care (comparison)
Number of subjects: 29760
Study 23509175 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29760
Study 21733566 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose Catumaxomab (10, 20, 50, and 100 μg)
Number of subjects: 45
Study 21733566 — intervention group
Group type: COMPARATOR
Intervention: Low dose Catumaxomab (10 μg)
Number of subjects: 45
Study 19811362 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA-rich Chlorella (20 mg as gamma-aminobutyric acid)
Number of subjects: 80
Study 19811362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18221627 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications
Number of subjects: 0
Study 18221627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14979754 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepotent Response Inhibition and Resistance to Distractor Interference
Number of subjects: 220
Study 14979754 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to Proactive Interference
Number of subjects: 220
Study 11498310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprivan (AstraZeneca, UK)
Number of subjects: 120
Study 11498310 — intervention group
Group type: EXPERIMENTAL
Intervention: Recofol (Leiras Oy, Finland)
Number of subjects: 120
Study 11498310 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Abbott)
Number of subjects: 120
Study 11498310 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprofol (Taro, Israel)
Number of subjects: 120
Study 9754979 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 1.2 mg twice daily
Number of subjects: 12
Study 9754979 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 12
Study 9754979 — intervention group
Group type: COMPARATOR
Intervention: Eformoterol with placebo
Number of subjects: 12
Study 9754979 — intervention group
Group type: EXPERIMENTAL
Intervention: Eformoterol with budesonide
Number of subjects: 12
Study 7828695 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms.day‐1)
Number of subjects: 28
Study 7828695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3414919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 0
Study 3414919 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 0
Study 3414919 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control)
Number of subjects: 0
Study 31383439 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology (30 min per session, once per day for 12 days)
Number of subjects: 72
Study 31383439 — intervention group
Group type: COMPARATOR
Intervention: Control (no reflexology)
Number of subjects: 72
Study 27521028 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐pulsed 1064‐nm‐Nd:YAG laser
Number of subjects: 20
Study 27521028 — intervention group
Group type: COMPARATOR
Intervention: no laser treatment (control group)
Number of subjects: 20
Study 25924674 — intervention group
Group type: EXPERIMENTAL
Intervention: Finding My Way Intervention (iCBT)
Number of subjects: 188
Study 25924674 — intervention group
Group type: COMPARATOR
Intervention: Attention-control condition
Number of subjects: 188
Study 23407407 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy alone (neck-specific exercises with a cognitive-behavioral approach)
Number of subjects: 63
Study 23407407 — intervention group
Group type: COMPARATOR
Intervention: ACDF followed by physiotherapy
Number of subjects: 63
Study 21442808 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture
Number of subjects: 58
Study 21442808 — intervention group
Group type: COMPARATOR
Intervention: Chinese medicine (Tianqi Tongjing Capsule)
Number of subjects: 58
Study 19674485 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented circuit class training (CCT) applied in groups of 4 to 6 patients, two times a week for 12 weeks.
Number of subjects: 220
Study 19674485 — intervention group
Group type: COMPARATOR
Intervention: Usual individual, face-to-face physiotherapy (Control group).
Number of subjects: 220
Study 16474093 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel treatment for both humans and buffaloes in Jishan
Number of subjects: 1000000
Study 16474093 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel treatment for humans only in Hexi
Number of subjects: 1000000
Study 16474093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for buffaloes in Jishan
Number of subjects: 1000000
Study 16474093 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical modeling
Number of subjects: 1000000
Study 15472458 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week structured education and exercise program (Group E)
Number of subjects: 35
Study 15472458 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Group C)
Number of subjects: 35
Study 11761389 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.015-inch skin grafts
Number of subjects: 0
Study 11761389 — intervention group
Group type: COMPARATOR
Intervention: 0.025-inch skin grafts
Number of subjects: 0
Study 9404589 — intervention group
Group type: EXPERIMENTAL
Intervention: Special outpatient clinic
Number of subjects: 2351
Study 9404589 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and advice group
Number of subjects: 2351
Study 9404589 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2351
Study 8495764 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin acetate (400 micrograms three times per day)
Number of subjects: 0
Study 8495764 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg/d)
Number of subjects: 0
Study 3120167 — intervention group
Group type: EXPERIMENTAL
Intervention: hp GRF 1‐44 amide
Number of subjects: 7
Study 3120167 — intervention group
Group type: COMPARATOR
Intervention: bromocriptine
Number of subjects: 7
Study 3120167 — intervention group
Group type: EXPERIMENTAL
Intervention: stress tests (insulin‐induced hypoglycaemia/glucagon)
Number of subjects: 7
Study 3120167 — intervention group
Group type: COMPARATOR
Intervention: TRH, GnRH and glucose tests
Number of subjects: 7
Study 29604403 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow loaded breathing (SLB)
Number of subjects: 32
Study 29604403 — intervention group
Group type: COMPARATOR
Intervention: Deep breathing control (CON)
Number of subjects: 32
Study 27696440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg raltegravir (q.d.) alone
Number of subjects: 14
Study 27696440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg raltegravir co-administered with 400 mg atazanavir (q.d.)
Number of subjects: 14
Study 27696440 — intervention group
Group type: COMPARATOR
Intervention: 400 mg atazanavir (q.d.)
Number of subjects: 14